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Background: 454 sequencing technology is a promising approach for characterizing HIV-1 populations and for
identifying low frequency mutations. The utility of 454 technology for determining allele frequencies and linkage
associations in HIV infected individuals has not been extensively investigated. We evaluated the performance of 454
sequencing for characterizing HIV populations with defined allele frequencies.
Results: We constructed two HIV-1 RT clones. Clone A was a wild type sequence. Clone B was identical to clone A
except it contained 13 introduced drug resistant mutations. The clones were mixed at ratios ranging from 1% to
50% and were amplified by standard PCR conditions and by PCR conditions aimed at reducing PCR-based
recombination. The products were sequenced using 454 pyrosequencing. Sequence analysis from standard PCR
amplification revealed that 14% of all sequencing reads from a sample with a 50:50 mixture of wild type and
mutant DNA were recombinants. The majority of the recombinants were the result of a single crossover event
which can happen during PCR when the DNA polymerase terminates synthesis prematurely. The incompletely
extended template then competes for primer sites in subsequent rounds of PCR. Although less often, a spectrum of
other distinct crossover patterns was also detected. In addition, we observed point mutation errors ranging from
0.01% to 1.0% per base as well as indel (insertion and deletion) errors ranging from 0.02% to nearly 50%. The point
errors (single nucleotide substitution errors) were mainly introduced during PCR while indels were the result of
pyrosequencing. We then used new PCR conditions designed to reduce PCR-based recombination. Using these
new conditions, the frequency of recombination was reduced 27-fold. The new conditions had no effect on point
mutation errors. We found that 454 pyrosequencing was capable of identifying minority HIV-1 mutations at
frequencies down to 0.1% at some nucleotide positions.
Conclusion: Standard PCR amplification results in a high frequency of PCR-introduced recombination precluding its
use for linkage analysis of HIV populations using 454 pyrosequencing. We designed a new PCR protocol that
resulted in a much lower recombination frequency and provided a powerful technique for linkage analysis and
haplotype determination in HIV-1 populations. Our analyses of 454 sequencing results also demonstrated that at
some specific HIV-1 drug resistant sites, mutations can reliably be detected at frequencies down to 0.1%.
Keywords: 454 pyrosequencing, HIV-1, Error rate, PCR induced recombination* Correspondence: shaow@mail.nih.gov
1Advanced Biomedical Computing Center, SAIC Frederick, Frederick National
Laboratory for Cancer Research, PO Box B, Frederick, MD, USA
Full list of author information is available at the end of the article
© 2013 Shao et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Shao et al. Retrovirology 2013, 10:18 Page 2 of 16
http://www.retrovirology.com/content/10/1/18Background
454 sequencing is a rapid, high throughput sequencing
technique used to obtain massively-parallel (or ultra-
deep) numbers of sequences. Multiplexing with the aid
of barcoded primers permits substantial numbers of in-
dependent samples to be analyzed simultaneously. High
throughput sequencing has greatly facilitated genomic
and metagenomic studies of a wide variety of organisms
and viruses [1,2] including whole genome sequencing
and detection of single nucleotide polymorphisms in
population-based screens. In general, these applications
involve analysis of a genetically uniform sample or mix-
tures of individual samples from diploid genomes en-
coding two alleles at specific loci. However, it has also
been applied to samples, such as virus populations, with
multiple alleles at a single site [3-11]. For example, 454
sequencing may be useful for detecting minority HIV
drug resistance mutations which may contribute to viro-
logic failure [12].
Several limitations inherent in the sequencing technol-
ogy or introduced during an initial PCR step require
careful consideration before ultradeep HIV sequencing
data from patients can be analyzed [13]. It is well known
that PCR amplification can introduce recombination
between templates. For example, it was reported that PCR
amplification of two distinct HIV-1 tat gene sequences
resulted in the formation of recombinant DNA sequences
in up to 5.4% of the amplified products. [14]. Other stud-
ies have reported >20% [15], and even 37% [16] of re-
combinant products after PCR amplification. These high
rates of in vitro recombination represent a substantial
limitation for determining linkage and haplotype compos-
ition [17,18]. Yet, descriptions of the effects of PCR-based
recombination in ultradeep sequencing derived data are
limited [19-24]. In addition, point errors introduced dur-
ing PCR and sequencing also limit its utility [25]. When
the goal is to determine the genome sequence of an or-
ganism, this inaccuracy can be compensated for by com-
paring sequencing reads with a reference and removing
any sequence with differences below a certain threshold.
For example in a study by Gilbert et al. [26], a threshold of
98% was used for determining sequence similarity resulting
in removing 15% of the sequence reads. An alternative ap-
proach is to assemble many overlapping sequences in order
to produce a consensus sequence at each position [27].
These approaches, however, are less useful when the goal
is to identify minority variants. Efforts have been made to
estimate the average and site-specific error rates by pyrose-
quencing. Hus, et al. studied the accuracy and quality of
454 sequencing on the V6 hypervariable region of cloned
microbial ribosomal DNA and estimated that the average
error rate was 0.49% per base [13]. Rozera et al. reported
an error rate of 454 sequencing on HIV-1 env quasispecies
of 0.97% in homopolymeric regions and 0.24% in non-homopolymeric regions [10]. Similarly, Wang et al. re-
ported that the sequencing error rate for four HIV plasmid
clones was 0.98% for all types of errors. These studies
mainly focused on the average error rate detected by 454
sequencing. Variation in error rate across nucleotide po-
sitions is uncertain. Determining the error rate at each
specific nucleotide position is essential for detecting low
frequency mutations at positions conferring HIV drug
resistance.
In the present study, we characterized the sensitivity
and accuracy of PCR amplification followed by 454 se-
quencing for detecting HIV-1 drug resistance mutations,
determined the sources for point errors and indels, and
measured the rate of PCR-based recombination. Further-
more, we modified the PCR conditions to reduce the
rate of recombination and improved the ability of this
technique to determine linkage between mutations and
haplotype composition in HIV-1 populations.
Results
To investigate error and recombination rates introduced
by the PCR and sequencing steps, three 454 sequencing
experiments (Runs 1, 2, and 3) were performed on PCR
products generated from HIV RT clones that were either
WT (Clone A) or contained 13 drug resistance mutations
(Clone B). A total of 774,322 sequences was obtained from
17 samples. Surprisingly, we observed that a few mutant
sequences were found in those samples that were supposed
to be 100% WT (2 sequences in Run1 MID2 (100% wt)
and 2 in Run2 MID2 (100% wt, Table 1). Infrequent WT
sequences were also found in the 100% mutant samples
(1 in Run1 MID3 (100% mutant) and 6 in Run2 MID3
(100% mutant, Table 1). These results could be due to
either a low level of cross contamination between clones
occurring while generating the panel of mutant to WT
mixtures, or cross contamination during primer synthesis,
leading to small fractions of primer DNA molecules with
the incorrect MID. In any case, the level of such cross
contamination was too low – approximately 0.01% - to
affect any of our conclusions.
Detection of PCR-based recombination
For the purpose of this study, recombinants were de-
fined as sequences that contained both wild type and
mutant bases at the specified drug resistant sites in a
single sequence. In Run1 and Run2, using standard PCR
conditions (Protocol 1 in methods), 454 sequencing de-
tected a high frequency of PCR-introduced recombin-
ation. For example, in Run1 MID7 (1% mutant/99% wt),
there were 0.9% recombinants and in MID5 (10% mu-
tant/90% wt) there were 8.42% recombinants. Detectable
recombinants increased to 14.82% in Run2 MID7 and
23.30% in Run2 MID9 (both 50% mixtures) (Table 1).
We recognized that some of the so called recombinants
Table 1 Detection of recombination during PCR
Sample Fragment Mixture Number of sequence





MID1 1 100% wild type 8503 8483 0 20 0.24% 0.00%
MID2 1 100% wild type 43699 43480 2 217 0.50% 0.00%
MID5 1 10% mutant 15923 12485 2039 1399 8.79% 8.42%
MID7 1 1% mutant 9548 9329 98 121 1.27% 0.90%
MID3 2 100% mutant 24210 1 24127 82 0.34% 0.00%
MID4 2 100% mutant 13466 0 13432 34 0.25% 0.00%
MID10 2 10% mutant 49169 35477 10156 3536 7.19% 6.90%
MID11 2 1% mutant 12070 11681 171 218 1.81% 1.51%
Run2
MID1 1 100% wild type 48828 48735 0 90 0.18% 0.00%
MID2a 1 100% wild type;
Clone DNA/no
PCR
98785 98670 2 113 0.11% 0.00%
MID5 1 100% mutant 52287 0 51903 384 0.73% 0.00%
MID7 1 50% mutant 58882 18565 31388 8929 15.16% 14.82%
MID9 1 50/50 mix RNA 54744 14151 27648 12945 23.65% 23.30%
MID3 2 100% mutant 60477 6 60297 174 0.29% 0.00%
MID4 2 100% wild type 38970 38705 0 265 0.68% 0.00%
Run 3
MID11 1 50% mutant 62437 21163 40777 497 0.78% 0.43%
MID12 1 50% mutant 122327 23589 83134 15604 12.00% 11.65%
a Run2MID2: Cloned DNA without PCR amplification.
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or a pure mutant molecule, or recombination with low
level cross contaminating templates. When we used 100%
WT or 100% mutant as controls (Run1 MID1, 2, 3, and 4;
Run2 MID1, 2, and 5), the background recombinant
frequencies ranged from 0.11% (Run2 MID2, 100% wt) to
0.73% (Run2 MID5, 100% mutant) (Table 1). Average
background recombinant frequencies were taken for each
run and were subtracted from the experimental values to
obtain corrected recombinant percentages (Table 1).
To attempt to reduce the extent of recombination, mod-
ifications were made to the PCR conditions, including a
higher concentration of each primer, a more processive
polymerase lacking 30 to 50 exonuclease proofreading ac-
tivity, longer elongation time, and fewer cycles of amplifi-
cation (Protocol 2 in methods). By incorporating these
modifications, we were able to reduce recombination rates
significantly. For example, in Run3 (50% mutant/50% wt)
recombinants were 0.43% (MID11, low recombination
PCR) compared to 11.65% by standard PCR (MID12,
standard PCR) (Table 1). Overall, changing the PCR
conditions resulted in a 27-fold reduction in detectable
recombinant sequences.We also compared the site-specific crossover frequen-
cies in two samples from Run3. Figure 1A shows the
frequency of crossovers in each interval for all the re-
combinant sequences detected. Generally, the longer the
interval between drug resistance sites, the more frequent
were the detectable crossovers in that interval. For ex-
ample, in Run3 MID12 (standard PCR, interval 1 (73 bps),
the crossover rate was 54% compared to 3.7% (Chi square
test, p < 0.0001) in interval 2 which was only 5 bases in
length (Figure 1A). Figure 1B shows the overall crossover
frequencies per base for the two PCR conditions. To in-
vestigate if different PCR conditions affected the number
of crossover events, the average crossover per base per re-
combinant sequence (AXBR) and the average crossover
per base per sequence (AXBS) were calculated. While
AXBR was similar in both samples, 0.56% in Run3 MID12
(standard PCR) and 0.69% in Run3 MID11 (low recom-
bination PCR), AXBS was significantly different, 0.07% in
Run3 MID12 and 0.006% in Run3 MID11 (Figure 1B).
This result indicates that the PCR conditions did not
affect the frequency of observed crossover events in a
sequence; rather, the low recombination PCR conditions
reduced the number of templates involved in recombination.
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Figure 1 Recombinant crossover rate estimation. (A) Observed crossover rates at each interval of recombinant sequences in Run3. The Y axis
is the crossover rate in percentage. The X axis shows the interval sites between each drug resistance site and the length of the intervals. (B)
Normalized average crossover rates. AXBR was obtained by dividing average crossover/base by total number of recombinant sequences. AXBS
was obtained by dividing average crossover/base by the total number of all sequences.
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served crossover events involving identical templates.
We used the 7 drug resistance sites as crossover detec-
tion signals in the fragment 1 samples. Theoretically, there
could be 1024 [11] different patterns because there were 7
intervals within which crossovers could be detected.
Seventy-five different crossover patterns (7% of all possible
patterns) were found in Run3 MID12 (standard PCR,
Table 2), and only 20 detectable patterns were observed
(2% of all possible) using the low recombination conditionsTable 2 Summary of recombination patterns
Run2 MID12 (standard PCR0)
# of patterns # of sequences
1 Crossover 12 12378
2 Crossover 28 1710
3 Crossover 28 188
4 Crossover 6 20
5 Crossover 1 1
Sum 75 14297of Run3 MID11 (low recombination PCR, Table 2). The
majority of recombinants were the result of single cross-
over events. Our results show that it was rare for 4 or more
crossovers to occur in a recombinant from Run2 MID12.
In fact, there were only 6 recombinants found with 4 cross-
over events out of 14,297 total recombinants and only a
single recombinant found from 5 crossover events in Run3
MID12 (Table 2). In Run3 MID11, there were 3 recom-
binants from 3 crossover events and no recombinants with
4 or 5 events (Table 2). The detailed crossover patternsRun3 MID11 (low recombination PCR)
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Figures 2 and 3 in which WT nucleotides are marked in
white and mutant nucleotides are marked in gray.
Detection of PCR/454 errors
Point mutations and indels can be introduced in both
the PCR and sequencing steps. Overall, with samples of
either 100% WT or 100% mutants (Run1 MID1-4, Run2
MID1-4, Table 3), we found that that 66.2% of the PCR/
454 generated sequences had at least one error, with
56.0% of these sequences having 1 or 2 errors per se-
quence (Table 3). These errors included both point muta-
tions and indels and varied considerably in frequency
from one MID (sample) to another within the same run.
To determine whether the error rate was biased relative to
one part of the sequence or another, we plotted the point
error distribution along the full length of Run1 fragment
1, combining the analyses of MID 1 (100% wt), 2 (100%
wt), 5 (10% mutant), 7 (1% mutant), 8 (0.1% mutant), and
9 (0.01% mutant, Figure 4A.) The point errors ranged
from 0.02% to 1.36% per base with a mean of 0.15 +/−
0.14% (Table 4). Point errors were distributed evenly along
the length of the sequences up to nucleotide position 206.
Note that positions 205, 206, 207, and 228 were in homo-
polymer regions (multiple contiguous identical nucleo-
tides) and positions 228–229 were at the 30 end of the
sequencing reads (Figure 4A). The high error rates at the
end of the sequences were due to pair-wise misalignments
(see Methods). Figure 4B shows that the indel frequency
in Run1 ranged from 0.002% to 49.99% with a mean of
0.51% +/− 4.16% (Table 4). The indels with high frequen-
cies (approximately ≥ 1%) were found in runs of As, which
are quite frequent in this fragment. Among those indels,
approximately 0.47% were deletions and 0.08% were inser-
tions. Similar trends for point errors (Figure 4C) and indel
errors (Figure 4D) were observed in Run2, where the cor-
responding averages were 0.12 ± 0.16% for point
mutations with the amplified samples and 0.25±1.1%
for indels with the amplified samples (Table 4). To deter-
mine the sources of the errors we cloned a 287 bp ampli-
con encompassing the fragment 1 region of interest and
all primers, keys and MIDs (Run2 MID2, 100% wt, cloned
without PCR) necessary for 454 sequencing so that it
could be directly sequenced without the PCR step.
Figure 4C shows that the point errors of the cloned sam-
ple (pink squares) ranged from 0.001% to 0.7% with a
mean of 0.02 +/− 0.06% (Table 4) compared to point
errors in PCR amplified samples (blue diamonds in
Figure 4C), which ranged from 0.008% to 1.06% with a
mean of 0.12 +/− 0.16% (Table 4, cloned vs. amplified, with
paired T test, p < 0.0001). This result shows that the major-
ity (more than 80%) of point errors occurred during PCR
amplification. By contrast, there was no difference in indel
errors between the cloned and PCR amplified samples,consistent with their generation during the 454 analysis.
Indels in the sequences from the cloned sample (pink tri-
angles in Figure 4D) ranged from 0.001% to 20.84% with a
mean of 0.25 +/− 1.14% while indels of amplified samples
(cyan squares in Figure 4D) ranged from 0.002% to 12.18%
with a mean of 0.25 +/− 1.10% (Table 4, cloned vs. ampli-
fied, with paired T test, p=0.74), indicating that most or all
of the indel errors resulted from the 454 sequencing. Over-
all, among those indels, deletions and insertions were
present at approximately the same frequency, 0.18%. We
also analyzed the error rates in Run 3 MID11 (low recom-
bination PCR) and in Run 3 MID12 (standard PCR). No
significant difference was found (0.08% in Run3 MID11,
low recombination PCR vs. 0.11% in Run3 MID12, stand-
ard PCR). However, if the error rates are normalized to
PCR cycles (45 cycles in Run3 MID11 vs. 25 cycles in
Run3 MID12), then the error rate per cycle in low recom-
bination condition was 0.0031% while the error rate per
cycle in the standard PCR condition was 0.0025%.
We further analyzed the results of these experiments
for the nature of the point errors introduced during the
PCR and sequencing steps. We found that base specific
point errors resulting from transitions (purine to purine
or pyrimidine to pyrimidine nucleotide changes) were
about 5–10 fold more frequent than those resulting from
transversions (pyrimidine to purine nucleotide changes
or vice versa) (Table 5). For example in Run1, transitions
ranged from 0.04% to 0.10% and transversions ranged
from undetectable (0.00%) to 0.03% (Table 5, Run1 frag-
ment1, T test P < 0.0001). Our data also show that the
specific error rate followed the order of A≥T>G>C
(Table 5) with A and T being the nucleotides most sus-
ceptible to error. Again, when the analysis was per-
formed on the same DNA fragment without PCR
amplification, the error rate was significantly lower. The
distribution pattern also is different from the amplified
samples (Table 5). For example, transitions were generally
more frequent than transversions in amplified samples, but
overlapped in the cloned sample (0.01 to 0.06 vs. undetect-
able (0.00 to 0.01) (Table 5). Additionally, the relative error
rates at different bases were different (C>G>A>T) (Table 5).
The difference of base-specific error rates between ampli-
fied samples vs. the cloned sample could be due to the na-
ture of the DNA polymerase used in PCR. To determine
the sensitivity of this approach to detect the drug resistance
mutations that can be found in this portion of RT, we
assessed the frequency of point errors at drug resistance
sites (Table 6). Mutations at these positions ranged from
undetectable (0.00%, L90I) to 0.31%, and were relatively
lower than that at non-drug resistance sites, largely reflect-
ing the preponderance of transversions in this set of muta-
tions. The error rate differed among the sites examined,
implying that mutations at some positions can be detected
with greater sensitivity than others (Table 6). For instance,
# of Sequences  % of total sequences
41 65 67 70 74 100 103
1 1 1 1 1 1 4039 3.3018%
1 3508 2.8677%
1 1 1849 1.5115%
1 1 1 1 1 1451 1.1862%
1 595 0.4864%
1 1 1 1 1 1 277 0.2264%
1 1 1 1 182 0.1488%
1 1 1 132 0.1079%
1 1 1 116 0.0948%
1 1 1 1 86 0.0703%
1 1 72 0.0589%
1 1 1 1 1 71 0.0580%
111 534 0.4365%
1 1 1 1 186 0.1521%
11 177 0.1447%
1 1 1 1 1 1 116 0.0948%
1 114 0.0932%
1 1 1 1 1 1 108 0.0883%
1 1 1 1 1 1 89 0.0728%
1 1 1 1 1 1 66 0.0540%
11111 39 0.0319%
1 36 0.0294%





1 1 1 1 1 1 22 0.0180%
1 20 0.0163%
1 1 1 19 0.0155%
11111 10 0.0082%
1 1 9 0.0074%
1111 8 0.0065%
1 1 5 0.0041%
1 1 1 3 0.0025%
111 2 0.0016%
11111 2 0.0016%
1 1 1 0.0008%
1 1 1 0.0008%
1 1 43 0.0352%
1 27 0.0221%
11 22 0.0180%
1 1 1 1 1 12 0.0098%
1 1 1 1 1 9 0.0074%
1 1 8 0.0065%
111 8 0.0065%




1 1 1 1 5 0.0041%
111 4 0.0033%
1111 3 0.0025%
1 1 1 1 1 3 0.0025%
111 2 0.0016%
1 1 1 1 2 0.0016%
1 1 1 1 2 0.0016%








1 1 1 1 0.0008%
1 1 1 1 1 0.0008%
1 1 1 1 1 1 0.0008%
1111 15 0.0123%
11 1 0.0008%
1 1 1 0.0008%
1 1 1 1 1 0.0008%
111 1 0.0008%
1 1 1 1 1 1 0.0008%
1 1 1 1 0.0008%
1307 1.0684%
Crossover Patterns
Figure 2 Crossover patterns of recombinant sequences from Run3 MID12 analyzed using standard PCR conditions. The second row
shows the drug resistance codon positions. The 1st to the 7th columns show the nucleotides at each of the 7 sites with WT marked in white and
mutant marked in gray. Detectable crossover events are shown as color changes (from white to gray or from gray to white). The last row
represents recombinants that have one or more nucleotides in the drug resistance codons missing from sequencing.
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# of sequences  % of total sequences
41 65 67 70 74 100 103
1 1 1 1 1 1 109 0.1746%
1 106 0.1698%
1 54 0.0865%
1 1 1 1 1 1 38 0.0609%
1 1 34 0.0545%
1 23 0.0368%
1 23 0.0368%
1 1 1 1 1 1 23 0.0368%
1 1 1 1 1 17 0.0272%
1 13 0.0208%
1 1 1 1 1 1 13 0.0208%
1 1 1 1 1 1 8 0.0128%
1 1 1 5 0.0080%
1 1 1 1 3 0.0048%
1 1 1 1 1 2 0.0032%
1 1 0.0016%
1 1 1 1 1 1 0.0016%
1 1 1 0.0016%
1 1 1 1 1 0.0016%
1 1 1 1 1 1 1 0.0016%
21 0.0336%
Crossover Patterns
Figure 3 Crossover patterns of recombinant sequences from Run3 MID11 obtained using low recombination PCR conditions. The
second row shows the drug resistance codon positions. The 1st to the 7th columns show the nucleotides at each of the 7 sites with WT marked
in white and mutant marked in gray. Detectable crossover events are shown as color changes (from white to gray or from gray to white). The
last row represents recombinants that have one or more nucleotides in the drug resistance codons missing from sequencing.
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higher sensitivity (0.02% background error rate, 95% CI
0.01 to 0.03) than K65R (A to G, 0.31% background error
rate, 95% CI 0.19 to 0.42). These position specific error
rates could be the result of both the particular base at the
position and the nucleotide context surrounding the bases.
We also calculated the percentage of drug resistant
mutants in the WT: mutant (clone A: clone B) mixtures
to further assess the sensitivity of detecting DRM
(Table 7). The observed ratios of mutant to WT were
not identical but fell within 2 fold of the expected values.
For example, in Run1 MID7 (1% mutant), the expected
percent of mutant sequences was 1%, and we detected
1.5%. In Run3 MID12 (standard PCR), we expected 50%
mutant, and found 74.6% mutant. At each drug resistant
site, the mutation frequencies were in general agreement
with the observed fraction of mutant reads. For example,
in Run1 MID5 (10% mutant), the observed number of
reads was 16.9% mutant. The percent mutant at the spe-
cific drug resistant site of D67W was 15.42% and at
K70R 17.01%. This sample, which contained an average
of 16.9% mutant, had a 95% confidence interval of the
mean of all seven drug resistant sites of 15.99-17.0%.
The same was true for all samples except one. In Run1
MID10 (10% mutant) the number of mutant reads was
22.3%, which was slightly higher than the 95% confi-
dence interval of the mean of all mutant fractions
(21.2%) in this sample. Table 7 also shows that in Run1-
MID7, in which there were 1% expected mutant reads,the percent of mutations at each codon ranged from 1.32%
to 1.63%. Considering that the point error rates were about
0.4% for the drug resistance sites overall (Table 6), it is rea-
sonable to estimate the sensitivity for these mutations at
1%. Consequently, mixtures containing 0.1% (Run1 MID8)
and 0.01% (Run1 MID9) mutant were not analyzed.
Discussion
In this study, we evaluated the ability of 454 sequencing
of PCR products to accurately portray HIV sequence
populations. Using mixtures of cloned DNA containing
wild type or mutant sequences at 13 sites associated
with resistance to RT inhibitors, we investigated the
frequency and mechanisms of point errors, indels, PCR-
introduced recombination, and the sensitivity for detect-
ing drug resistance mutations in three independent runs.
We looked initially at recombination. We defined a
recombinant sequence as one containing both WT and
mutant residues generated from mixtures of the two
clones. This method is limited by a small background
resulting from its inability to determine if a single
nucleotide change resulted from a point error or from a
(usually double) recombination event in the intervals be-
tween drug resistance sites. Furthermore, we were not
able to observe recombination between identical paren-
tal sequences. To maximize detectable crossover events,
we used 50% wt/mutant mixtures. As our result shows
(Table 7), the measured wt/mutant ratios were not
exactly 50%. This likely reduced the observed
Table 3 Distribution of errors per sequence
Sample (total sequences) 0 errors 1 errors 2 errors 3 errors 4 errors 5 errors 6–10 errors >10 errors All sequences with errors
Run1MID1 (8305) 24.23% 44.32% 18.62% 8.04% 3.05% 1.01% .067% 0.06% 6293 (75.77%)
Run1MID2 (43699) 25.50% 14.47% 36.56% 15.79% 4.68% 1.53% 1.42% 0.05% 32556 (74.50%)
Run1MID3 (24210) 67.16% 24.51% 5.03% 1.62% 0.85% 0.43% 0.40% 0.02% 7951 (32.84%0
Run1MID4 (13466) 69.69% 22.70% 4.60% 1.45% 0.63% 0.40% 0.52% 0.00% 4081 (30.31%)
Run2MID1 (48825) 23.23% 43.26% 20.37% 7.09% 2.59% 1.27% 1.80% 0.40% 37483 (76.77%)
Run2MID2 (98785) 0.12% 65.26% 23.88% 6.17% 2.33% 0.96% 1.08% 0.20% 95665 (99.88%)
Run2MID3 (60477) 66.18% 23.57% 5.90% 1.96% 0.79% 0.51% 0.98% 0.09% 20451 (33.82%)
Run2MID4 (38970) 60.18% 26.66% 7.64% 2.42% 1.03% 0.70% 1.27% 0.12% 15517 (39.82%)
Number of sequences (336737) 113740 129224 59438 19843 7031 3056 3875 526 222997 (66.22%)














Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 Point error and indel error estimation. (A). Point error distribution in Run1 fragment 1. The data are from Run1 MID1, 2, 5, 7, 8, and
9. The X axis is the nucleotide position of sequences, with position 1 corresponding to nucleotide 101 in BH10 RT [29]. The Y axis is the mean
error rate of all samples at each position (blue diamonds). The error bars correspond to 1 standard deviation. The orange diamonds at the top
show the locations of drug resistance sites. The numbers with arrows indicate nucleotide positions of sites with high error rates. The gray boxes
show the 20 nucleotide PCR primer regions. (B) Indel error distribution in Run1 fragment 1, combined MID1, 2, 5, 7, 8, and 9. The Y axis is the
mean indel error rate of all samples at each position (blue squares). The error bars correspond to 1 standard deviation of the error rate of each
position. Other symbols are as in panel A. The numbers in parentheses indicate the number of As in homopolymer regions. (C) Point error
distribution in Run2 fragment 1. The data are from Run2 MID1, 5, 7, and 9. Conventions are as in panel A. The pink squares show point errors
from cloned sample DNA (MID2). Blue diamonds show the mean error rate of all other samples at each position. (D) Indel error distribution from
Run2 MID1, 5, 7, and 9. Conventions as in panel B Pink squares show the indel errors of cloned sample DNA. Blue squares are the mean indel
error rate of all other samples at each position. The colored symbols and vertical lines after the second gray box show the average errors and
standard deviations.
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http://www.retrovirology.com/content/10/1/18recombination. To differentiate whether a mutation in a
WT molecule (or a wild type nucleotide in a mutant
molecule) is from a point mutation error or from a
crossover event, we sequenced clones of 100% WT and
100% mutant samples as controls. Indeed, in experi-
ments in Run1 and Run2, we observed “recombinants”
from pure samples at a frequency of 0.11% to 0.73%.
Sequences from these samples were not likely to have
been recombinants but probably the result of point
errors. For our analyses, these small values were sub-
tracted from observed results with mixtures to obtain
corrected recombination frequencies (Table 1). Our
results show that standard PCR used for sample prepar-
ation produced a remarkably high frequency of
artifactual recombination. Generally, frequency of cross-
overs depended on the length of intervals. However, base
compositions appeared to affect the crossover rate as
well [14]. Tsibris et al. [28] reported that in vitro recom-
bination was infrequent (0.11% to 0.15%) in a mixture of
3 different clones with the minor species at 1%. We
observed 0.9% to 1.5% recombinants in our experiment
with 1% mutant clone in a WT background (Table 1),
meaning that more than half of the mutant sequences
were involved in crossovers.. The different recombin-
ation rates in the two studies may be partially explained
by different experimental designs (3 clone mixture vs. 2
clone mixture), different parental sequences (HIV-1 env
V3 loop vs. HIV-1 pol), or different PCR conditions.
Hedskog et al. [21], and Mild, et al. [22] reported 0.89%
of in vitro recombination in their studies. That is lower
than the frequency we obtained. The reasons could be
[16] the length of the fragment they used to detect
crossovers of 14 signature nucleotides (RT amino acidTable 4 Summary of point and indel errors arising during PCR
Point mutation %
Minimal Maximal Mean
Run1 0.02 1.36 0.15
Run2 amplified 0.008 1.06 0.12
Run2 cloned (MID2) 0.001 0.72 0.02positions 181, 184, 188, 190, 210, 215, and 219) is
shorter than ours (positions 41, 65, 67, 70, 74, 100, 103,
181, 184, 188, 190, 215, 219) [29]. We have signature nu-
cleotide from positions 41 to 103. The differences of the
intervals and the sequence compositions from position
41 to 181 partially explain the different recombination
rates observed. Additionally, Gorzer et al. [19] showed
that artifactual recombination significantly correlated with
the initial amount of DNA used for PCR amplification.
Mild et al. [22] used 100,000 templates in PCR and
observed 0.89% recombinants while we used 1,000,000
templates in our PCR and observed 11.65% recombinants.
PCR mediated recombination results from incompletely
extended primers annealing to heterologous templates
and extending in the next round of elongation [14,16]. By
modifying PCR conditions to reduce the probability of
premature termination, we found that that PCR mediated
recombination could be reduced by 27 fold.
We next examined point and indel errors known to
arise during PCR and ultradeep sequencing. It has been
previously reported that the error rates differ at homopo-
lymer regions and non-homopolymer regions [10,13,18].
We found that the point errors were evenly distributed ex-
cept at homopolymer regions, particularly near the 30 end
of the sequenced region. This discrepancy is even more
dramatic in indel error distributions. A high frequency of
indel errors was found primarily in homopolymer regions
(Figures 4B and 4D). Additionally, we found that, overall,
in our study of the HIV-1 RT region, that there were more
deletions than insertions in our samples. This is different
from the observation by Vandenbroucke et al. [24]. They
reported 0.07%–0.14% insertions and 0.02% to 0.08% dele-
tions in their study of the HIV-1 env V3 region. Thisand 454 sequencing
Indel mutation
Std Minimal Maximal Mean Std
0.14 0.002 49.99 0.51 4.16
0.16 0.002 12.18 0.25 1.10
0.06 0.001 20.84 0.25 1.14
Table 5 Base-specific error rate a
Correct base Read as:
Run1 A C G T Total
A 0.02% 0.10% 0.02% 0.13%
C 0.01% 0.01% 0.04% 0.05%
G 0.09% 0.01% 0.01% 0.10%
T 0.03% 0.08% 0.02% 0.13%
Run2 amplified b A C G T Total
A 0.00% 0.07% 0.02% 0.09%
C 0.00% 0.00% 0.03% 0.03%
G 0.05% 0.00% 0.01% 0.06%
T 0.01% 0.05% 0.01% 0.07%
Run2 clone (MID2) A C G T Total
A 0.00% 0.04% 0.01% 0.05%
C 0.01% 0.00% 0.06% 0.07%
G 0.04% 0.00% 0.01% 0.05%
T 0.01% 0.01% 0.00% 0.02%
a Transition errors are marked in bold.
b Run2 amplified samples include MID1 (100% wt), 2 (100% wt, no PCR), 5
(100% mutant), 7 (50% mutant), and 9 (50% mutant); Run2 clone is
Run2 MID2.
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http://www.retrovirology.com/content/10/1/18difference may be related to sequence context [24]. Man-
ual examination of the sequence alignment confirms that
more deletions were produced in homopoly A regions,
particularly the region near RT K103. Also, we noticed
that the deletion/insertion rate was different between
Run1 and Run2 while point mutation errors were very
similar. This different deletion/insertion rate may reflect
variation in performance of 454 sequencing from one run
to the next. We also found that transversion errors were
5–10 fold lower than transition errors (Table 5). Huse
et al. reported that A to G and T to C changes were more
frequent than other types of changes [13]. Our results
show that the frequencies of transitions exhibited a smallTable 6 Point errors at drug resistance mutation sites
Position Mutation Run1 Run2 b Highest of 2 run (95 CI)
21 M41L(A->C) 0.02% 0.01% 0.02% (0.01 to 0.03)
94 K65R(A->G) a 0.31% 0.09% 0.31(0.19 to 0.42)
99 D67W(G->A) 0.07% 0.02% 0.07% (0.01 to 0.13)
109 K70R(A->G) 0.09% 0.06% 0.09% (0.03 to 0.16)
120 L74V(T->G) 0.02% 0.00% 0.02% (0.00 to 0.01)
198 L90I(T->A) 0.00% 0.00% 0.00% (0.00 to 0.03)
209 K103N(A->C) 0.02% 0.01% 0.02% (0.01 to 0.03)
210 K103N(A->T) 0.02% 0.02% 0.02% (0.01 to 0.03)
a Transition errors are in bold.
b Run1 includes MID1 (100% wt), 2 (100% wt), 5 (10% mutant), 7 (1% mutant);
Totally 77,673 sequences analyzed . Run2 includes MID1 (100% wt), 2 (100%
wt), 5 (100% mutant), 7 (50% mutant), 9 (50% mutant); Totally 313,523
sequences analyzed.bias in the same direction, but that all transitions were
nonetheless more frequent than transversions.
Ultradeep sequencing has been used to identify low
frequency drug resistance mutations [3,6,11]. Mitsuya
et al. proposed that it was unlikely that variants at a
frequency > 1.0% resulted from sequencing errors. They
used 1% as the cut-off for drug resistance sites and 2%
for other RT sites [6]. A similar result was obtained by
Gilles et al. [30]. Based on 100% wild type or 100% mu-
tant samples, we show that it is possible to use a sub-
stantially lower cutoff for some drug resistance sites
because error rates were considerably lower at some
sites than at others. For example, the background of
K103N (A to C) and, K103N (A to T) were each 0.02%,
and L74V (T to G) was 0.02%, with 95% confidence
bounds of 0.01 to 0.03, and 0.00 to 0.03, respectively
(Table 6). We measured the fractions of mutations in
samples with mixed wild type and mutant sequences
(Table 7) and found that frequencies at each site were in
good agreement with expected values down to about 1%.
It seems clear from these results, however, that it is
possible to use this technology to measure the frequency
of specific mutations, particularly transversions, down to
less than 0.1%, similar to that achievable with allele-specific
PCR [31]. In such cases, however, it is essential -- and not
particularly difficult -- to include internal controls of
cloned DNA (or transcripts prepared from cloned DNA)
to assess the actual background frequencies achieved in
any experiment.
The sources for point errors in 454 generated
sequences were from both the PCR and the sequencing
steps. Although errors resulting from sequencing have
been reported to result in part from more than one mol-
ecule being bound to a single bead before the emulsion
PCR [13], this artifact cannot have caused the errors
observed in sequencing cloned DNA. In any case, our data
show that PCR contributed the majority (0.12+/−0.16% of
PCR amplified vs. 0.02+/−0.06% of cloned, DNA Table 4)
of the point error rate and that sequencing contributed
primarily to indel errors. This conclusion was also sug-
gested by Vandenbroucke et al. [24].
We observed 0.01% cross contamination in our studies
(Table 1, Run1 MID2 (100% wt), MID3 (100% mutant),
and Run2 MID2 (100% wt, cloned without PCR). This
effect could have resulted from laboratory error, but
could also be due to cross contamination in primer syn-
thesis resulting in mislabeling of a fraction of a sample
with an incorrect MID. We have also shown that a high
frequency of recombination could be introduced by stand-
ard PCR conditions. However by using the low recombin-
ation PCR conditions described here, 454 sequencing
technology can be a useful tool in studying mutation link-
age and haplotype composition. Our results also have
shown that, while indel errors were more frequently found
Table 7 Drug resistance mutation detection in mixed samples
Sequences DRM at each codon %
Sample Expectecd mutant % Observed mutant %
Fragment 1 mutations M41 K65 D67 K70 L74 L160 K103 Mean 95% CI
Run1MID5 10 16.9 16.21 16.94 15.42 17.01 16.79 16.4 16.67 16.49 15.99-17.0
Run1MID7 1 1.50 1.48 1.63 1.32 1.57 1.51 1.45 1.33 1.47 1.37-1.55
Run2MID7 50 61.58 60.26 60.91 60.08 61.53 61.38 61.64 62.24 61.15 60.43-61.87
Run2MID9 50 63.24 61.56 62.60 61.96 630 62.99 62.85 64.10 62.72 61.97-63.48
Run3MID11 50 65.69 65.71 65.67 650 65.69 65.68 65.71 65.72 65.60 65.35-65.84
Run3MID12 50 74.63 74.41 74.48 73.92 74.43 74.32 74.59 75.29 74.49 74.11-74.87
Fragment 2 mutations Y181 M184 Y188 G190 L205 T215 T215 K219
Run1MID10 10 22.26 20.35 20.77 21.05 21.07 21.38 21.35 21.37 22.15 21.19 20.75-21.63
Run1MID11 1 2.24 2.18 2.43 2.40 2.21 1.94 1.76 1.73 1.84 2.06 1.83-2.30
Mean: Mean percentage of all drug resistance codons;
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sequencing, point errors were more or less evenly distrib-
uted in the whole region, and occurred mainly during
PCR. We found that drug resistance sites had lower point
error rates compared to other sites, implying that it is pos-
sible to detect rare drug resistance mutations with high
sensitivity.
In this study, we observed higher than expected
mutants/wt ratios (Table 7). The differences between the
expected and observed ratios could be due to the fact that
a sequence read was defined as a mutant or wild type by
BLAST comparing it to the wild type reference and the
mutant reference. If it aligned better with wild type refer-
ence (with higher E score), then it was defined as wild
type. For the purpose of Table 7, we did not separate
recombinants as we did for Table 1; all sequences were
assigned either to wild type or mutant. Figure 2 shows the
recombination patterns in Run3MID12. It shows that the
numbers of the crossover product pairs were not exactly
the same. There are more sequences with more gray
regions (mutations) than the white regions (wild type).
Therefore, more putative recombinants in Table 7 were
defined as mutants. Ratios of the mixtures were verified
by ASP prior to deep sequencing so the higher than
expected mutant sequences are likely due to PCR or se-
quencing bias.
Recently, Jabara et al. [32] reported an experiment sys-
tem in which a randomly synthesized 8 base segment
(“primer ID”) was incorporated into the primer for
cDNA synthesis. Consensus sequences were built from
the products of PCR amplification and used for muta-
tions detection. By consensus sequence construction,
minor sequencing errors and recombination produced
by PCR can be removed.
Methods
Construction of mutant plasmids
Site directed mutagenesis was performed on an HIV-1
BH10 WT molecular plasmid clone (designated clone A)
[29] to generate a multi-drug resistant mutant clone con-
taining the following RT mutations: 41L, 65R, 67N, 70R,
74V, 100I, 103N, 181C, 184V, 188C, 190A, 215Y, 219Q
(designated Clone B). The full sequence has been depos-
ited in GenBank under accession number JX198552.
Preparation of WT and mutant transcripts
An 895 bp PCR product from codon 22 to 291 in RT
was amplified from each of the HIV-1BH10 WT and mu-
tant plasmids and cloned into pPCR-Script Amp SK (+)
transcription vector using the PCR-Script Amp Cloning
Kit (Stratagene). Transcripts were made from each
clone, using the RiboMax transcription kit (Promega),
quantified spectrophotometrically at 260 nm, diluted to
108 copies/μl, divided into aliquots and stored at -80°C.Primer design for use with the 454 standard genome
Sequencer system
The Roche Genome Sequencer (GS) FLX System pro-
vides sequence reads up to approximately 250 bases. In
order to investigate two regions of interest in the HIV-1
RT region that included a number of well characterized
drug resistance mutations, primers were designed for
fragment 1, a 265 base pair (bp) amplicon encoding
amino acids 41 thru 103 of RT, and fragment 2, a 160bp
amplicon encoding amino acids 181 thru 219. To se-
quence 12 samples containing the RT region of interest
in run 1, 12 forward primers of 49 bp were designed for
fragment 1 and consisted of 4 parts: sequencing primer
A, (50GCCTCCCTCGCGCCA30), a key (TCAG), a 10
bp Multiplex Identifier (MID; also known as a barcode;
see Additional file 1: Table S1) to differentiate among
samples, and the HIV target-specific region (50TAGTAG
AAATTTGTACAGAA30). The reverse primer (39bp) for
fragment 1 consisted of 3 parts: sequencing primer B,
(50GCCTTGCCAGCCCGC30), the same key, and the
target region (50TCCAGTACTGTTACTGATTT30) and
was used for all fragment 1 samples. The 12 forward 454
primers for fragment 2 were also 49 bp and consisted of
the same sequencing primer A, key, and MID sequences
but a different target region (50 AAAATCCAGACA
TAGTTATC 30). The reverse primer for fragment 2
(50GCCTTGCCAGCCCGCTCAGGGAGGTTCTTTCT
GATGTTT30) was 39 bp and was used for all fragment 2
samples. These same primers were also used for runs 2
and 3.
454 Runs and samples
In all, 3 separate 454 runs were performed on 17 sam-
ples (Table 1). Among these samples, 9 were either 100%
wild type or 100% mutant, serving as controls to detect
background point and indel error rate. The rest were
mixtures of wild type and mutant and used for measur-
ing recombination and for detecting specific low level
drug resistance mutations.
Preparation of the clone for PCR error control
To differentiate the errors introduced by PCR from
the errors introduced by pyrosequencing a bacterially-
grown clone was sequenced directly (without PCR). To
generate the clone the WT plasmid was amplified
with primers 3-1F, 50GCCTCCCTCGCGCCATCAGACG
CTCGACATAGTAGAAATTTGTACAGAA30 and 4-1R,
50GCCTTGCCAGCCCGCTCAGACGCTCGACATCCA
GTACTGTTACTGATTT30. The resulting product
included the forward and reverse sequencing primers A
and B, the key, MID 2 and the HIV target region from
fragment 1. This 265 bp piece was cloned into a pPCR-
Script Amp SK (+) vector. The clone was transformed into
ultracompetent cells, expanded, purified and digested with
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ially grown DNA encompassing all primers, keys and
MIDs necessary for the successful 454 sequencing of frag-
ment 1.
Preparation of mixtures and PCR conditions
Both the WT and mutant plasmid clones were quantified
spectrophotometrically, and mixed at ratios of mutant to
WT at 100%, 50%, 10%, 1%, 0.1%, 0.01%, and 0%. To en-
sure the accuracy of the ratios, mixtures were analyzed
by allele specific PCR (ASP; data not shown) [31]. All
mixtures resulted in a final copy number of 106 total
copies/μl. The plasmid mixtures were amplified in two
fragments using the following PCR conditions (Protocol
#1): 400 nM each primer, 200 μM dNTPs, 4 mM MgSO4,
1X Hi Fi Buffer (Invitrogen) and 2.5 units Hi Fidelity Plat-
inum Taq (Invitrogen). Following a 2 minute thermal acti-
vation of the Taq at 95°, 45 cycles of PCR amplification
were performed with each cycle consisting of 95° for 30 sec,
50° for 30 sec and 72° for 30 sec.
In addition, the 50:50 mixtures were amplified using a
low recombination PCR protocol (Protocol #2) as fol-
lows: 1μM each primer, 200μM dNTPs, 2.3mM MgCl2,
1X Taq Gold buffer, 5 units Taq Gold (Applied Bio-
systems). Following a 15 minute thermal activation of
the Taq at 95°, 25 cycles of PCR amplification was per-
formed with each cycle consisting of 95° for 15 sec, 51°
for 30 sec and 68° for 1 min 30 sec. All final PCR
products, as well as the MID 2 clone grown in E. coli,
were quantified using the QuantiFluo DNA Assay Kit
(BioAssay Systems) and ~1012 copies of each sample was
sent to be sequenced using the Roche Genome Sequen-
cer (GS) FLX System.
Preparation of samples from RNA transcripts
WT and mutant RNA transcripts were mixed at a 50:50
ratio to result in final copy numbers of 2×105, 2×104,
and 2×103 copies/μl. Each mixture was used as template
with the following conditions: 1X reaction mix (Invitro-
gen SuperScript One-Step RT-PCR kit) and 200nM each
primer. The reactions were denatured at 65º for 10 min-
utes and placed on ice. RT/Platinum Taq enzyme (Invi-
trogen) (1μl) was added to each reaction and placed
under the following thermocycling conditions: 50º for 30
min, 94º for 2 min, 57.5º for 30 sec, and 70º for 40sec
for 35 cycles.
Sequencing error rate estimation
Sequence reads from the 454 sequencing were sorted
into different sample sets according to their MID. After
removing the 10 base MID, sequences were aligned to
the wild type sequence or the mutant sequence using
blastn in BLAST program. A Perl script was written to
parse the pair-wise alignments. Any sequence shorterthan the length of the reference by 20 or more bases was
removed from further analysis. Additionally, ambiguous
base calls were not used in the analyses. Because blastn
will produce deletions at the ends of alignments, if a
mutation or indel at or near the end of the read, leading
to a truncation of a sequence, a function was con-
structed in the script to compare the 50 region with
reference sequences and correct errors at the 50 end to
restore the truncated fragments. No effort was taken to
correct the misalignment at the 30 end due to the fact
that this portion was in the 30 primer region which is not
amplified during PCR and was not used for mutation or re-
combinant detection. This procedure therefore produced
high error rates at the 30 ends (Figures 4A and 4C). To esti-
mate the sequencing error rate, sequencing reads were
compared with the reference for each site, any nucleotide
difference between a sequencing read and the reference
cloned DNA used as template was treated as a sequencing
error.
Recombination detection and rate estimation
To estimate recombination rates each sequence was
aligned to the WT or mutant reference sequence. If a se-
quence was more similar (based on a smaller E value
produced by BLAST) to the WT reference then it was
considered WT; otherwise, it was considered mutant. If
a sequence contained a combination of WT and mutant
nucleotides at the 13 drug resistance sites, it was counted
as recombinant. This approach could overestimate the
number of recombinant sequences if mutations were
introducing by PCR error. This potential artifact was eval-
uated using control experiments with 100% wide type
samples (Table 1, Run 1 MID1 (100% wild type) MID2
(100% wt); Run 2 MID1 (100% wt) MID2 (100% wt with-
out PCR amplification)) or 100% mutant samples (Table 1,
Run1, MID3 (100% mutant), MID4 (100% mutant); Run 2,
MID1-5 (from 100% wt to 50% mutant). And the recom-
binant frequency was adjusted accordingly.
For crossover rate estimation in each interval between
the 13 signature nucleotides, the number (N) of sequences
with wild type nucleotide at one site and mutant nucleo-
tide at the other site was counted. The crossover rate in
an interval was calculated by dividing the number of
crossover events in this interval (N) by the total crossover
events in all 6 intervals (T) being expressed in percentage
(N/T * 100).
Frequency of drug resistance mutations in mixtures
Sequences were assigned to be WT or mutant based on
the E value produced by BLAST and percentages were
calculated from those assignments. The number of drug
resistant mutations (DRM) at each of the 13 drug resist-
ance sites was calculated the same way as the sequen-
cing error estimate (above) from these mixed samples.
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the number of sequences containing each DRM by the
total number of reads (WT and mutant) in a sample
minus the number of sequences containing deletions in
the DRM site.
Statistical test
Studentcs T-test, Chi Square test, and confidence in-




Standard PCR amplification results in a high frequency of
PCR-introduced recombination precluding its use for link-
age analysis of HIV populations using 454 pyrosequencing.
We designed a new PCR protocol that resulted in a much
lower recombination frequency and provided a powerful
technique for linkage analysis and haplotype determination
in HIV-1 populations. Our analyses of 454 sequencing
results also demonstrated that at some specific HIV-1 drug
resistant sites, mutations can reliably be detected at fre-
quencies down to 0.1%.
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